울트라제닉스제약(주)
US ˙ NasdaqGS ˙ US90400D1081

SecurityRARE / Ultragenyx Pharmaceutical Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership1,959 shares
Latest Disclosed Value $ 71,229
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 5.59% decrease in ownership of RARE / Ultragenyx Pharmaceutical Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 1,959 shares of Ultragenyx Pharmaceutical Inc. (US:RARE) valued at $71,229 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 2,075 shares of Ultragenyx Pharmaceutical Inc.. This represents a change in shares of -5.59% during the quarter. The current value of the position is $45,664 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Ultragenyx Pharmaceutical EC US90400D1081 1,959 -116 -5.59 71 -5.33 0.7916
2025-05-29 2025-03-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,075 97 4.90 75 -9.64 0.7982
2025-03-03 2024-12-31 NP Ultragenyx Pharmaceutical EC US90400D1081 1,978 13 0.66 83 -23.85 0.8342
2024-11-29 2024-09-30 NP Ultragenyx Pharmaceutical EC US90400D1081 1,965 -220 -10.07 109 22.47 0.9887
2024-08-29 2024-06-30 NP Ultragenyx Pharmaceutical EC US90400D1081 2,185 -139 -5.98 90 -17.59 0.8187
2024-05-30 2024-03-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,324 -122 -4.99 109 -6.90 0.9202
2024-02-29 2023-12-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,446 -34 -1.37 117 31.82 0.9587
2023-11-29 2023-09-30 NP Ultragenyx Pharmaceutical EC US90400D1081 2,480 644 35.08 88 4.76 0.7655
2023-08-28 2023-06-30 NP Ultragenyx Pharmaceutical EC US90400D1081 1,836 -261 -12.45 85 0.00 0.6684
2023-05-30 2023-03-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,097 -1,256 -37.46 84 -45.81 0.6369
2023-02-28 2022-12-31 NP Ultragenyx Pharmaceutical EC US90400D1081 3,353 469 16.26 155 30.25 0.9394
2022-11-29 2022-09-30 NP Ultragenyx Pharmaceutical EC US90400D1081 2,884 271 10.37 119 -23.23 0.8334
2022-08-29 2022-06-30 NP Ultragenyx Pharmaceutical EC US90400D1081 2,613 14 0.54 156 -17.55 1.0695
2022-05-26 2022-03-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,599 -222 -7.87 189 -20.68 1.1153
2022-02-28 2021-12-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,821 374 15.28 237 7.73 1.0482
2021-11-29 2021-09-30 NP Ultragenyx Pharmaceutical EC US90400D1081 2,447 -68 -2.70 221 -7.95 0.9277
2021-08-27 2021-06-30 NP Ultragenyx Pharmaceutical EC US90400D1081 2,515 199 8.59 240 -9.13 1.0044
2021-05-27 2021-03-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,316 276 13.53 264 -6.74 1.1866
2021-03-01 2020-12-31 NP Ultragenyx Pharmaceutical EC US90400D1081 2,040 -1,646 -44.66 282 -6.62 1.1501
2020-11-25 2020-09-30 NP Ultragenyx Pharmaceutical EC US90400D1081 3,686 -227 -5.80 303 -1.31 1.2644
2020-08-27 2020-06-30 NP Ultragenyx Pharmaceutical EC US90400D1081 3,913 -938 -19.34 306 42.33 1.2335
2020-06-01 2020-03-31 NP Ultragenyx Pharmaceutical EC US90400D1081 4,851 -309 -5.99 216 -2.27 1.3192
2020-03-02 2019-12-31 NP Ultragenyx Pharmaceutical EC US90400D1081 5,160 392 8.22 220 8.37 1.0201
2019-11-27 2019-09-30 NP Ultragenyx Pharmaceutical EC US90400D1081 4,768 4,768 204 1.0821
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.